IP Library Granted Patent US 7,056,534
Granted Patent B2
US 7,056,534 · App. 10/921,789 · Granted Jun 6, 2006

Coated potassium chloride granules and tablets

Assignee: Upsher-Smith Laboratories, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,056,534
App. No.
10/921,789
Granted
Jun 6, 2006
Kind
B2
Abstract

This invention provides extended release potassium chloride granules consisting essentially of potassium chloride crystals having a mesh size of about 20–60 mesh that are coated only with ethylcellulose. The granules may be compressed into tablets that disintegrate rapidly in an aqueous environment to provide uniform dissolution of the potassium chloride. Tablets containing about 10 to about 20 milliequivalents potassium may be formulated in accordance with the invention. Processes to produce extended release granules without using surfactants, processing aids or other coating aids are also provided by this invention. A method is further provided whereby a patient's supplemental potassium requirements are met by administering an appropriate combination of dosage units chosen from available dosage units containing different quantities of potassium.

Claims (18)

1. A method for customizing a patient's supplemental potassium dosage requirement of about 25–80 mEq potassium comprising:

i) providing at least two individual pharmaceutical dosage units from the group consisting of a first individual dosage unit containing about 10 mEq potassium, a second individual dosage unit containing about 15 mEq potassium, and a third individual dosage unit containing about 20 mEq potassium; and

ii) administering a suitable combination of the 10 mEq, 15 mEq, and/or 20 mEq individual dosage units that in single or multiple administration meets the patient's supplemental potassium requirement,

wherein each of the dosage units is an extended-release tablet comprising a plurality of granules consisting of potassium chloride crystals between about 20–60 mesh and having a continuous coating consisting of a single thermoplastic cellulose ether.

2. A method according to claim 1 , wherein the administering is done occasionally.

3. A method according to claim 1 , wherein the administering is done as a daily regimen.

4. A method according to claim 1 , wherein the thermoplastic cellulose ether is ethylcellulose.

5. A method according to claim 1 , wherein the single or multiple administration provides a dosage in the range of about 25–45 mEq potassium.

6. A method according to claim 1 , wherein the patient's supplemental potassium dosage requirement is about 30 mEq potassium or about 45 mEq potassium, and individual pharmaceutical dosage units containing about 15 mEq potassium are provided.

7. A method for customizing a patient's supplemental potassium dosage requirement of about 25–80 mEq potassium comprising:

i) providing at least two individual pharmaceutical dosage units from the group consisting of a first individual dosage unit containing about 10 mEq potassium, a second individual dosage unit containing about 15 mEq potassium, and a third individual dosage unit containing about 20 mEq potassium; and

ii) administering a suitable combination of the 10 mEq, 15 mEq, and/or 20 mEq individual dosage units that in single or multiple administration meets the patient's supplemental potassium requirement,

wherein each of the dosage units is an extended-release tablet comprising a plurality of granules consisting of potassium chloride crystals essentially free of surfactants or processing aids and agents, between about 20–60 mesh, and having a continuous coating consisting of a single thermoplastic cellulose ether.

8. A method according to claim 7 , wherein the administering is done occasionally.

9. A method according to claim 7 , wherein the administering is done as a daily regimen.

10. A method according to claim 7 , wherein the thermoplastic cellulose ether is ethylcellulose.

11. A method according to claim 7 , wherein the single or multiple administration provides a dosage in the range of about 25–45 mEq potassium.

12. A method according to claim 7 , wherein the patient's supplemental potassium dosage requirement is about 30 mEq potassium or about 45 mEq potassium, and individual pharmaceutical dosage units containing about 15 mEq potassium are provided.

Assignments (6)
CHANGE OF NAME Recorded Jun 12, 2017
From: UPSHER-SMITH LABORATORIES, INC.
To: UPSHER-SMITH LABORATORIES, LLC
Reel/Frame 042765/0909 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JP MORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: UPSHER-SMITH LABORATORIES, INC.
Reel/Frame 042548/0136 →
RELEASE OF PATENT SECURITY INTEREST Recorded Aug 17, 2016
From: TCF NATIONAL BANK
To: UPSHER-SMITH LABORATORIES, INC.
Reel/Frame 039735/0329 →
SECURITY AGREEMENT Recorded Jun 13, 2012
From: UPSHER-SMITH LABORATORIES, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028371/0759 →
SECURITY AGREEMENT Recorded Dec 2, 2009
From: UPSHER-SMITH LABORATORIES, INC.
To: TCF NATIONAL BANK
Reel/Frame 023586/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2004
From: CHRISTENSON, BRADLEY L.; DRITSAS, PHILLIP W.
To: UPSHER-SMITH LABORATORIES, INC.
Reel/Frame 015396/0365 →
Continuity (3)
Continuation 1007689200 · Feb 14, 2002
Continuation In Part 1004007000 · Oct 23, 2001
Related Publication 20050079219A1 · Apr 14, 2005